B2BROKER-GROUP
26.8.2021 15:04:33 CEST | Business Wire | Press release
B2Broker Group is pleased to officially announce the launch of its venture fund, B2Broker VC. B2Broker VC is led by a team that is one of the most successful and fast-growing financial technology groups with in-depth expertise in sectors ranging from IT development to capital management. The venture fund will enable the investment in, and nurture of external projects that are of interest such as new fintech startups and payment systems, and will create synergies for the group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210826005497/en/
First Ventures
Back in 2017, like many other tech industry giants, B2Broker Group started working on its own internal corporate venture fund. This was focused on the development of a number of specific projects. Since then, the capitalisation of the group’s fund has grown steadily and now includes a number of projects in which the company has invested over $15 million so far. This is an exciting project which has enabled the development of a modern financial and technological ecosystem on the basis of the B2Broker group of companies.
Of particular focus is the launch of B2BinPay in 2017, a payment system which has become one of the most modern and technologically progressive platforms in the world, B2BX , a platform for the trading of digital assets which is licenced in the EU, Eqwire, a digital banking service, and last but not least, the group’s most expensive and complex project, B2Prime, which is an integrated liquidity provider with licences in different jurisdictions, including Europe and CIS.
External Projects
With the experience acquired on these internal projects and the business-processes that have been developed, B2Broker VC has also started investing in external projects. One of the most noteworthy of these is the innovative Coinsbuy, a project designed to cater for the growing demand for buying crypto using a credit or debit card. This will be a complementary project to B2Broker’s ecosystem.
Throughout this process, B2Broker VC identified the most interesting sectors such as fintech, IT development and automation, as well as startups offering products for the brokerage market.
Procedures and Stages
The most important aspect that the group seeks in its partners is conscientiousness, a clear vision and a good understanding of the market. B2Broker VC considers all potential recipients of investments as long-term strategic partners who in partnership, will move towards global leadership in the various market sectors.
B2Broker VC always finds the most convenient way of investment and cooperation both through equity holding and via convertible loans, which make the terms of cooperation as flexible as possible.
Companies who wish to apply for funding follow a step-by-step procedure starting with the preparation of an application and documents. This is followed by a product performance evaluation, follow-up questions and a series of meetings and evaluations before the final decision is made. After the signing of various documents and agreements, the first tranche of investment will be released after a process which takes between 2-6 months.
The kind of projects that are of interest to B2Broker VC are ones that match the group’s goals and business model. These include:
● Fintech development: Products and services for Forex, securities, derivatives, CFD and crypto markets.
● IT development: Development of payment systems, trading and brokerage platforms, risk management systems, analytical systems.
We are particularly interested in companies who have Bridges Technology and plugins for MT4/5, Trading Platforms for FX/CFD trading and those who have built trading platforms for Crypto Perpetual Futures, Crypto Spot trading and Securities trading on Exchanges. We are also looking for HUB and liquidity aggregation solutions and technology for market making on crypto exchanges.
● Automation: Products in the field of automation of external systems and process automation services.
● Products/services suitable for B2Broker's ecosystem such as KYC solutions, marketing services, products and services for the brokerage market.
Companies that end up working with the B2Broker Group will be handed the keys to the development of a young company that includes both financial assistance and access to the group’s infrastructure, its offices, and development teams, as well as top financial and marketing expertise.
Applications
B2Broker VC carefully considers each application received and investigates the possible mechanisms of cooperation, regardless of the size of the company and entrepreneurial experience among the founders.
To submit your application and become a global leader with B2Broker VC email us at vc@b2broker.com or visit our website .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210826005497/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
